[Acetylsalicylic acid in the primary and secondary prevention of vascular disease].
Schrör
K
K
Institut für Pharmakologie und Klinische Pharmakologie, UniversitätsKlinikum Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Deutschland. Karsten.Schroer@uni-duesseldorf.de
Nitschmann
S
S
D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D002543:Cerebral Hemorrhage / Q000139:chemically induced / Q000401:mortality; D005858:Germany; D006470:Hemorrhage / Q000139:chemically induced / Q000401:mortality; D006801:Humans; D009203:Myocardial Infarction / Q000401:mortality / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D055502:Secondary Prevention; D020521:Stroke / Q000401:mortality / Q000517:prevention & control*; D015996:Survival Rate; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D001241:Aspirin